September 12, 2024

Otto Meyerhof Medal for Hendrik Dietz

Otto Meyerhof Medal for Hendrik Dietz

In recognition of his outstanding scientific achievements, Joachim Spatz, Managing Director of the Max Planck Institute for Medical Research in Heidelberg, honored Hendrik Dietz from the Technical University of Munich with the Institute’s Otto Meyerhof Medal.

A highlight of the two-day Meyerhof Symposium: Joachim Spatz, Managing Director of the MPImF, awards the Otto Meyerhof Medal to Hendrik Dietz from the Technical University of Munich (© MPImF).

In a festive ceremony at the Max Planck Institute for Medical Research (MPImF) in Heidelberg, Joachim Spatz awarded the Otto Meyerhof Medal to the German biophysicist Hendrik Dietz and honored his achievements: “Hendrik Dietz is the leading scientist who has succeeded in bringing physical principles of nanoscopic, molecular building blocks into medically relevant applications. He is the ideal recipient of the Otto Meyerhof Medal.”

Meyerhof Lecture on “Molecular machines of the future”
The award was preceded by the Meyerhof Lecture, which is given by the medal winners and was established in 1997. In his lecture entitled “Molecular machines of the future”, Hendrik Dietz outlined his goal of building molecular devices and machines that can be combined to form autonomously functioning systems and perform user-defined tasks. To achieve this goal, he wants to adapt and use the physical principles underlying the formation of natural molecular motors and viruses. He explained how he goes about this in his lecture.

In memory of Otto Meyerhof
The Meyerhof Lecture was established in 1997 and takes place every two years. The medal has been awarded and combined with it since 2021. This year, both the Meyerhof Lecture and the medal ceremony were the focus of a two-day symposium of the same name. It took place on September 9 and 10 in memory of Nobel Prize winner Otto Meyerhof, one of the founders of the MPImF. He headed the Department of Physiology from its founding year in 1929 until 1938, when the living and working conditions under National Socialism became unbearable for him as a Jew and he, along with other Jewish employees of the institute, fled Germany.

Guest of honor from California: Meyerhof‘s granddaughter arrives
Otto Meyerhof fled to the USA, where he died in 1951. His descendants still live there today. The MPImF made contact with them and invited Ruth Emerson, one of Otto Meyerhof‘s granddaughters, to the Symposium. Ruth Emerson brought unique historical objects with her on her trip to Heidelberg: the stethoscope and the dissection tools that belonged to Otto Meyerhof and with which he himself worked. On the occasion of the Symposium, Ruth Emerson donated them to the Institute – a generous gift that enriches the MPImF‘s historical exhibition.

Symposium with a top-class program
The program of the Meyerhof Symposium 2024 offered lectures by leading scientists from various fields of research: Andrea Ablasser (EPFL), Frank Noé (FU Berlin), Ilaria Testa (SciLifeLab), Eric Schreiter (HHMI Janelia), Michael Schmitt (Heidelberg University Hospital) and Xiao Wang (Broad Institute). The audience consisted of scientists from the Institute, the entire scientific community of Heidelberg and many other interested guests.

Original News

Our latest News

discover more
Digital recording of health status

Digital recording of health status

Successful pilot project at Heidelberg University Hospital Regularly surveying patients about their health-related quality of life is a key aspect of patient-centred medicine. At Heidelberg University Hospital, a new digital system is being used for this purpose in a pilot project: patients complete online questionnaires on their own mobile devices, after which the data is […]

A mouse model for Dry Eye Disease

A mouse model for Dry Eye Disease

Experimentica utilizes a validated mouse model of dry eye disease. Dry eye disease-like pathology is induced using transdermal scopolamine patches in combination with desiccating environmental stress. The induced pathology is characterized using corneal fluorescein staining, tear volume measurements, and histology for lacrimal gland infiltration, goblet cell loss, and corneal abnormalities. Dry eye disease, also referred […]

Gilead to Acquire Tubulis Adding Potentially Best-In-Class Antibody-Drug Conjugate and Next Generation Platform to Further Strengthen Oncology Pipeline

Gilead to Acquire Tubulis Adding Potentially Best-In-Class Antibody-Drug Conjugate and Next Generation Platform to Further Strengthen Oncology Pipeline

Foster City, Calif., and Munich, Germany – April 7, 2026 – Gilead Sciences, Inc. (Nasdaq: GILD) today announced it has entered into a definitive agreement to acquire Tubulis GmbH, a private Germany-based, clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADCs), building on Gilead’s oncology pipeline, focused on addressing areas of high unmet need. The acquisition significantly […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp